Respiratory Diseases

The Respiratory Group focuses on the discovery and development of novel therapies against a broad range of respiratory diseases, from common to rare (genetic) diseases, such as cystic fibrosis.  Their strategy is to deliver solutions for unmet medical needs in the respiratory area.

The Respiratory Group concentrates on cystic fibrosis, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, chronic obstructive pulmonary disease and asthma.

 

 

Selected publications

• Danahay H.; Atherton H.C.; Jackson A.D.; Kreindler J.L.; Poll C.T.; Bridges R.J. Membrane capacitance and conductance changes parallel mucin secretion in the human airway epithelium. Am J Physiol Lung Cell Mol Physiol. (Mar, 2006); 290(3): L558-69.
• Sawicka E.; Dubois G.; Jarai G.; Edwards M.; Thomas M.; Nicholls A.; Albert R.; Newson C.; Brinkmann V.; Walker C. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity.   J Immunol. ( Dec 15, 2005); 175(12): 7973-80.
• Ali K.; Bilancio A.; Thomas M.; Pearce W.; Gilfillan A.M.; Tkaczyk C.; Kuehn N.; Gray A.; Giddings J.; Peskett E.; Fox R.; Bruce I.; Walker C.; Sawyer C.; Okkenhaug K.; Finan P.; Vanhaesebroeck B. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature. (Oct 21, 2004); 431(7011): 1007-11.